Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibialmyxedema: A Case Series. Severe pretibialmyxedema (PTM) can be difficult to manage, highlighting the need to investigate newer therapies. Rituximab (RTX) and intravenous immunoglobulin (IVIg) have been tried in Graves' orbitopathy. Since PTM and orbitopathy share a similar underlying pathophysiology, this study
Treatment of pretibialmyxedema with intralesional immunomodulating therapy Local immune regulation therapy has been one of the therapeutic methods used for the treatment of autoimmune thyroid disease in patients with pretibialmyxedema (PTM). However, the poor response rate and high recurrence rate are still major problems. Whether a premixed corticosteroid, compound betamethasone, could
Injected Hyaluronidase Reduces the Volume of Exogenous Hyaluronate Fillers in Mice and Results in Clinical Improvement in a Patient with PretibialMyxedema Hyaluronidases are essential for the breakdown of hyaluronate (HA) in tissues and may be used to prevent the adverse effects of HA fillers. We explored the effect of hyaluronidase on exogenous and endogenous HA in vitro and in vivo. HA fillers were incubated with different concentrations of hyaluronidase and visualized by electrophoresis. HA fillers were injected in the skin of hairless mice, and 4 h later hyaluronidase was injected in the papules of exogenous HA. Hyaluronidase was injected in the nodule of pretibialmyxedema of a male patient with Graves' disease. Skin sections of mice and of the patient were performed, and a skin
Morphological Diversity of PretibialMyxedema and Its Mechanism of Evolving Process and Outcome: A Retrospective Study of 216 Cases Background. Pretibialmyxedema (PTM) is a rare dermopathy. The morphologic features and mechanism of its evolving process are not reported in large case series. Methods. 216 cases with PTM were retrospectively reviewed to analyze demographics, history, lesional
A Randomized Controlled Trial of Intralesional Glucocorticoid for Treating PretibialMyxedema. Pretibialmyxedema (PTM) is an uncommon dermopathy associated with autoimmune thyroid diseases. Now it is thought to be autoimmune and its treatment with glucocorticoid is helpful. However, it has not been evaluated. A prospective randomized controlled trial was performed in 110 patients with PTM
, with a level of evidence considered low, that IVIg are efficacious in six indications. The CPG recommendations and the clinicians perspective concur and permit recommending IVIg to treat pemphigoid and as a 3 treatment option for three indications: necrobiotic xanthogranuloma, pretibialmyxedema and livedoid vasculopathy. In two indications, atopic dermatitis and urticaria, the clinicians consulted suggested
xanthogranuloma, atopic dermatitis, urticaria, pretibialmyxedema, pemphigoid and livedoid vasculopathy. For one indication, Stevens-Johnson syndrome or toxic epidermal necrolysis, the results of primary studies or systematic reviews of primary studies indicate, based on an overall level of evidence considered moderate to low, that adding IVIg to a treatment known to be effective against this condition does
, including lymphedema (due to radical mastectomy or lymphatic disease) as well as pretibialmyxedema (which occurs as a result of deposition of glycosaminoglycans). Pitting edema can occur in the early stages of lymphedema because of an influx of protein-rich fluid into the interstitium, before fibrosis of the subcutaneous tissue; therefore, its presence should not exclude the diagnosis
of corticosteroidsScleredema In patients with a severe form of the condition In the event of failure, contraindication or intolerance to the other therapeutic optionsScleromyxedemaNecrobiotic xanthogranuloma Pyoderma gangrenosum Pretibialmyxedema Livedoid vasculopathy 1. Based on the clinical experience of the expert committee’s members, for patients with dermatomyositis, IVIg can be considered on an exceptional basis
of corticosteroidsScleredema In patients with a severe form of the condition In the event of failure, contraindication or intolerance to the other therapeutic optionsScleromyxedemaNecrobiotic xanthogranuloma Pyoderma gangrenosum Pretibialmyxedema Livedoid vasculopathy 1. Based on the clinical experience of the expert committee’s members, for patients with dermatomyositis, IVIg can be considered on an exceptional basis
these conditions. The results of the systematic reviews indicate, with a level of evidence considered low, that IVIg are efficacious in six indications. The CPG recommendations and the clinicians perspective concur and permit recommending IVIg to treat pemphigoid and as a 3 treatment option for three indications: necrobiotic xanthogranuloma, pretibialmyxedema and livedoid vasculopathy. In two indications
xanthogranuloma, atopic dermatitis, urticaria, pretibialmyxedema, pemphigoid and livedoid vasculopathy. For one indication, Stevens-Johnson syndrome or toxic epidermal necrolysis, the results of primary studies or systematic reviews of primary studies indicate, based on an overall level of evidence considered moderate to low, that adding IVIg to a treatment known to be effective against this condition does